CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 22 enrolled
Drug / intervention
Eribulin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02623972
NCT02623972Phase 2Active
CompareCT.gov

A Phase 2 Study of Eribulin Followed by Doxorubicin and Cyclophosphamide as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Dana-Farber Cancer Institute·interventional·Posted Dec 8, 2015·Updated Nov 25, 2025

In Brief

A Phase 2 clinical trial evaluating Eribulin, Adriamycin, and 1 other intervention for Inflammatory Breast Cancer and Human Epidermal Growth Factor 2 Negative Carcinoma of Breast. Active but no longer recruiting, targeting 22 participants across 2 sites.

Detailed Summary

This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
CountriesUnited States
CollaboratorsEisai Inc.

Timeline

Phase 2Active
201620172018201920202021202220232024202520262027
First PostedDec 8, 2015
Enrollment StartFeb 26, 2016
Primary CompletionMay 1, 2021
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 10.6 years ago

Interventions

Eribulindrug

administered IV for 4 cycles

Adriamycindrug

administered IV with cyclophosphamide for 4 cycles

Cyclophosphamidedrug

administered IV with adriamycin for 4 cycles